|  | 
|  |  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
|   
 
    
    
    
I have compiled some of the DD here for ROIX Joseph Clark recently resigned and upon the resignation the stock fell from a $3.00 level to -$1.00  I am of the belief that upon the appointment of a new CEO the stock will regain it previous level making it an excellent investment at this time. Dr. West is currently filling the position of CEO and is truly the moving force behind this organization. Follow the URL?s below to the PR?s and do your own DD, I thing you will find this a good investment. PR URL: siliconinvestor.com ROIX is a comprehensive cancer management co. that provides advanced cancer treatment services, manages the practices of oncologists, and conducts cancer research on behalf of pharmaceutical companies. For the 9 months ended 9/98, revenues rose 24% to $94.1M. Net income rose 24% to $3.9M. Revenues reflect an increase in revenue from the practice management division. Earnings reflect a decrease in interest expense and provision for doubtful accounts. Response Oncology, Inc. 1775 Moriah Woods Blvd. Memphis, TN 38117 Phone: (901) 761-7000 Fax: (901) 763-7045 Employees: 425 Officers: William H. West, Chmn., Frank M. Bumstead, Vice Chmn., Joseph T. Clark, Pres./CEO, Mary E. Clements, Exec. VP-Fin./CFO, Kenneth L. Scott, COO. Sales (TTM): 128.25M | ||||||||||||
| 
 
 | 
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |